Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BBM 2478A; BMY 28090; Elsamicin A; NSC 369327; SPI-28090

Latest Information Update: 14 Apr 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Spectrum Pharmaceuticals
  • Class Aminoglycosides; Benzopyrans; Cytostatic antibiotics
  • Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours
  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 14 Apr 2016 No recent reports on development identified - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in USA (IV)
  • 21 Apr 2011 Elsamitrucin is available for licensing in World (excluding USA) as of 21 Apr 2011. http://www.spectrumpharm.com/
  • 21 Apr 2011 Phase-I clinical trials in late-stage Solid tumours (in combination with paclitaxel) in USA (IV) before April 2011
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top